Chen Bihua's Form 4 filing
BlossomHill Therapeutics, Inc. (BLSM) · filed Aug 10, 2026
- Accession no.
- 0001231919-26-000852
- Filed
- Aug 10, 2026, 6:32 PM ET
- Trade date
- Aug 6-10, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 3 derivative transactions. Open-market purchases total $5.00M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Chen BihuaCIK 0001599214 | Director, 10% Owner |
| Cormorant Asset Management, LPCIK 0001583977 | 10% Owner |
| Cormorant Global Healthcare Master Fund, LPCIK 0001618442 | 10% Owner |
| Cormorant Private Healthcare Fund III LPCIK 0001817320 | 10% Owner |
| Cormorant Private Healthcare Fund V LPCIK 0001969296 | 10% Owner |
| Cormorant Private Healthcare Fund VI, LPCIK 0002098185 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Common Stock | CConversionAcquired | +1,599,993 | –F2 | – | 1,599,993 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionAcquired | +1,701,541 | –F2 | – | 3,301,534 | Indirect | |
| Aug 10, 2026 | Common Stock | PPurchaseAcquired | +312,500 | $16.00 | +$5,000,000 | 3,614,034 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | Common Stock | AGrant or awardAcquired | +23,904 | $0.00 | $0 | 23,904 | Direct | Duplicate filing |
| Aug 10, 2026 | Common Stock | CConversionDisposed | −1,599,993 | –F2 | – | 0 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionDisposed | −1,701,541 | –F2 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
Referenced by the price of 2 transactions in Table I and 2 transactions in Table II.
Remarks
Master Fund, Fund III, Fund V and Fund VI may be deemed directors by deputization by virtue of their representation on the board of directors of the Issuer.